Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
September 15, 2015
NIH Awards $7.5 Million Grant For AgeneBio HOPE4MCI Phase 3 Clinical Trial To Delay The Onset Of Alzheimer’s Dementia
AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health (NIH).
